Characterization of mouse models, combined with biochemical and immunohistologic validation from post-mortem tauopathy brain tissues, as well as genetic evidence from human transcriptomic studies, may continue to help us investigate the pathogenesis of glial tau pathology and its impact on the pathology of primary tauopathies. The gene discussed is MAPT; the disease is tauopathy.